RS53769B1 - Imunogena jedinjenja koja sadrže hiv gp41 peptid spojen na crm197 belančevinu-nosioc - Google Patents
Imunogena jedinjenja koja sadrže hiv gp41 peptid spojen na crm197 belančevinu-nosiocInfo
- Publication number
- RS53769B1 RS53769B1 RS20150035A RSP20150035A RS53769B1 RS 53769 B1 RS53769 B1 RS 53769B1 RS 20150035 A RS20150035 A RS 20150035A RS P20150035 A RSP20150035 A RS P20150035A RS 53769 B1 RS53769 B1 RS 53769B1
- Authority
- RS
- Serbia
- Prior art keywords
- peptide
- immunogenic compound
- formula
- hiv
- immunogenic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K17/00—Carrier-bound or immobilised peptides; Preparation thereof
- C07K17/02—Peptides being immobilised on, or in, an organic carrier
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
- A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- AIDS & HIV (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305602.0A EP2668959B1 (en) | 2012-05-31 | 2012-05-31 | Immunogenic compounds comprising HIV gp41 peptide coupled to CRM197 carrier protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS53769B1 true RS53769B1 (sr) | 2015-06-30 |
Family
ID=48793339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20150035A RS53769B1 (sr) | 2012-05-31 | 2012-05-31 | Imunogena jedinjenja koja sadrže hiv gp41 peptid spojen na crm197 belančevinu-nosioc |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9511136B2 (enExample) |
| EP (2) | EP2668959B1 (enExample) |
| JP (1) | JP6352251B2 (enExample) |
| KR (1) | KR102077876B1 (enExample) |
| CN (1) | CN104507496B (enExample) |
| AU (1) | AU2013269120B2 (enExample) |
| BR (1) | BR112014029861B1 (enExample) |
| CA (1) | CA2875162C (enExample) |
| DK (1) | DK2668959T3 (enExample) |
| EA (1) | EA027803B1 (enExample) |
| ES (2) | ES2528109T3 (enExample) |
| HR (1) | HRP20150058T1 (enExample) |
| IN (1) | IN2014DN10128A (enExample) |
| MX (1) | MX360206B (enExample) |
| PL (1) | PL2668959T3 (enExample) |
| PT (1) | PT2668959E (enExample) |
| RS (1) | RS53769B1 (enExample) |
| SI (1) | SI2668959T1 (enExample) |
| UA (1) | UA118542C2 (enExample) |
| WO (1) | WO2013179262A1 (enExample) |
| ZA (1) | ZA201409023B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140335119A1 (en) * | 2004-02-06 | 2014-11-13 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL |
| SG11201708247XA (en) * | 2015-04-17 | 2017-11-29 | Biolife Science Qld Ltd | A vaccine composition and uses thereof |
| WO2016184963A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| WO2016184973A1 (en) * | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| WO2016184962A1 (en) | 2015-05-19 | 2016-11-24 | Innavirvax | Treatment of hiv-infected individuals |
| EP3574915A1 (en) * | 2018-05-29 | 2019-12-04 | Neovacs | Immunogenic product comprising il-4 and/or il-13 for treating disorders associated with aberrant il-4 and/or il 13 expression or activity |
| EP4115900A1 (en) * | 2021-07-05 | 2023-01-11 | Diaccurate | Novel antigens and vaccines |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1445614A1 (en) * | 2003-02-06 | 2004-08-11 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | A method for the in vitro assessment of the progression status of an HIV virus in an invidual |
| KR101201120B1 (ko) * | 2003-12-17 | 2012-12-03 | 와이어쓰 엘엘씨 | Ａβ 면역원성 펩티드 캐리어 컨쥬게이트 및 이의 제조 방법 |
| EP2331565A2 (en) * | 2008-08-28 | 2011-06-15 | Aarhus Universitet | Hiv-1 envelope polypeptides for hiv vaccine |
| US7965010B2 (en) * | 2008-09-03 | 2011-06-21 | Bose Corporation | Linear motor with patterned magnet arrays |
| WO2010040853A1 (en) * | 2008-10-10 | 2010-04-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A method for the screening of candidate substances active against the infection of a subject by a hiv virus and kits for performing the said method |
-
2012
- 2012-05-31 DK DK12305602.0T patent/DK2668959T3/en active
- 2012-05-31 PL PL12305602T patent/PL2668959T3/pl unknown
- 2012-05-31 ES ES12305602.0T patent/ES2528109T3/es active Active
- 2012-05-31 SI SI201230130T patent/SI2668959T1/sl unknown
- 2012-05-31 EP EP12305602.0A patent/EP2668959B1/en active Active
- 2012-05-31 RS RS20150035A patent/RS53769B1/sr unknown
- 2012-05-31 PT PT123056020T patent/PT2668959E/pt unknown
-
2013
- 2013-05-30 CN CN201380041048.0A patent/CN104507496B/zh active Active
- 2013-05-30 UA UAA201412809A patent/UA118542C2/uk unknown
- 2013-05-30 US US14/404,254 patent/US9511136B2/en active Active
- 2013-05-30 EP EP13737420.3A patent/EP2854846B1/en active Active
- 2013-05-30 ES ES13737420T patent/ES2701084T3/es active Active
- 2013-05-30 WO PCT/IB2013/054482 patent/WO2013179262A1/en not_active Ceased
- 2013-05-30 CA CA2875162A patent/CA2875162C/en active Active
- 2013-05-30 EA EA201491969A patent/EA027803B1/ru not_active IP Right Cessation
- 2013-05-30 MX MX2014014526A patent/MX360206B/es active IP Right Grant
- 2013-05-30 AU AU2013269120A patent/AU2013269120B2/en active Active
- 2013-05-30 IN IN10128DEN2014 patent/IN2014DN10128A/en unknown
- 2013-05-30 BR BR112014029861-0A patent/BR112014029861B1/pt active IP Right Grant
- 2013-05-30 KR KR1020147036531A patent/KR102077876B1/ko active Active
- 2013-05-30 JP JP2015514666A patent/JP6352251B2/ja active Active
-
2014
- 2014-12-09 ZA ZA2014/09023A patent/ZA201409023B/en unknown
-
2015
- 2015-01-16 HR HRP20150058AT patent/HRP20150058T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI379839B (en) | Aβ immunogenic peptide carrier conjugates and methods of producing same | |
| KR102077876B1 (ko) | Ｃｒｍ１９７ 담체 단백질에 커플링된 ｈｉｖ ｇｐ４１ 펩티드를 포함하는 면역원성 화합물 | |
| US8936789B2 (en) | Immunoenhancer-linked oligomeric HIV envelope peptides | |
| US20250109175A1 (en) | Recombinant gp120 protein with v1-loop deletion | |
| NZ740816A (en) | Compositions against cat allergy | |
| JP2010506926A (ja) | Ｉｉ−Ｋｅｙ増強ワクチンの効力 | |
| Phatarphekar et al. | RelCoVax®, a two antigen subunit protein vaccine candidate against SARS-CoV-2 induces strong immune responses in mice | |
| WO2016184962A1 (en) | Treatment of hiv-infected individuals | |
| JP6152944B2 (ja) | 束縛免疫原性組成物およびその用途 | |
| WO2016184973A1 (en) | Treatment of hiv-infected individuals | |
| US11452769B2 (en) | Mosquito saliva protein malaria vaccine | |
| WO2018085488A1 (en) | Universal mammalian influenza vaccine | |
| JP2010500407A (ja) | Ｈｉｖ−１の複数の株及びサブタイプを治療及び予防するための組成物及び方法 | |
| JP2001505763A (ja) | Ｈｉｖ ｐ―１７ペプチドフラグメント、それを含有する組成物並びにその製造及び使用方法 | |
| Nevagi | Structure-activity relationship of GAS lipopeptide vaccine candidates in TMC-based self-adjuvanting delivery system. | |
| Cunliffe | The rational structure-based design of a protein nanoparticle presenting a chimeric MenB antigen | |
| EA048154B1 (ru) | Иммуногенные соединения |